A carregar...
Management of immune checkpoint inhibitor‐related rheumatic adverse events
Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938753/ https://ncbi.nlm.nih.gov/pubmed/31762209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13249 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|